Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | F7 | P08709 | 1/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.32 |
| ▸ | ACHE | P22303 | 5/20 | 0.32 |
| ▸ | BCHE | P06276 | 3/20 | 0.32 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2135811 | 0.85 | PRKAB2 (0.40) | KMT2AACHEBCHELMNA | |
| Bicarbonate SCHEMBL16239727 | 0.84 | F10 (0.37) | F10F11F7RARARARB | |
| SCHEMBL2136437 | 0.83 | RARB (0.37) | F10F11F7RARARARB | |
| SCHEMBL2136556 | 0.82 | F11 (0.43) | F10F11F7RARARARB | |
| SCHEMBL2135919 | 0.81 | PARP14 (0.38) | F10F11F7 | |
| SCHEMBL2133078 | 0.80 | PDGFRB (0.40) | F10F11F7 | |
| SCHEMBL2730591 | 0.78 | F7 (0.43) | F10F11F7RARARARB | |
| SCHEMBL2133027 | 0.78 | F10 (0.33) | F10F11F7 | |
| SCHEMBL2135630 | 0.76 | F7 (0.37) | F10F11F7KMT2AABCB1 | |
| SCHEMBL2134584 | 0.76 | F7 (0.37) | F10F11F7ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630124-B1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | claimed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | claimed |
| EP-2630124-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-08-28 | — | — | EP | claimed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | claimed |
| WO-2012052372-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-26 | — | — | WO | claimed |
| EP-2630124-B1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| EP-2630124-B1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2630124-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-08-28 | — | — | EP | disclosed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | disclosed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | disclosed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | disclosed |
| WO-2012052372-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012052372-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | PRKAG1, PRKAB1, PRKAG2 | F10 4686/4885F11 4766/4885F7 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.